GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?

Biotech bigwig Gilead Sciences, Inc. (GILD) is scheduled to report second-quarter 2025 results on Aug. 7, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $6.95 billion and $1.95 per share, respectively. Earnings estimate for 2025 has increased to $8.02 from $7.91 per share over...